Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
buprenorphine/naloxone
BICYCLE THERAPEUTICS
Opioid Use Disorder
1 trial -
butylphthalide(NBP)
The First People's Hospital of Lianyungang
Acute Ischemic Stroke
1 trial -
carbidopa, levodopa, entacapone
Novartis Pharmaceuticals
Parkinson's Disease
1 trial -
dapagliflozin
The First People's Hospital of Lianyungang
Diabetic Kidney Disease
1 trial -
dexlansoprazole
Takeda
Laryngopharyngeal Reflux
1 trial -
dexmedetomidine
The First People's Hospital of Lianyungang
Postoperative Cognitive Dysfunction
1 trial -
dexmedetomidine
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Sleep Quality of Patients Undergoing TURP
1 trial -
dexmedetomidine
The First People's Hospital of Lianyungang
Aged
3 trials -
dexmedetomidine hydrochloride for injection
The First People's Hospital of Lianyungang
Delirium
1 trial -
diclofenac sodium topical gel
Teva Pharma GmbH
Multiple Sclerosis
1 trial -
dipyridamole
United Therapeutics Europe Ltd
Coronary Artery Disease
1 trial -
entecavir
The First People's Hospital of Lianyungang
Liver Fibrosis
1 trial -
ginkgolide
The First People's Hospital of Lianyungang
Intravenous Alteplase Thrombolysis
1 trial -
glatiramer acetate
Teva Pharma GmbH
Multiple Sclerosis
2 trials -
glatiramer acetate injection with oral cetirizine hydrochloride
Teva Pharma GmbH
Multiple Sclerosis
1 trial -
half-dose ticagrelor
The First People's Hospital of Lianyungang
Acute Coronary Syndrome
1 trial -
handwashing
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Communicable Diseases
1 trial -
hyaluronic Acid + platelet-rich plasma
Regeneron Ireland Designated Activity Company (DAC)
Knee Osteoarthritis
1 trial -
hydrochloride hydromorphone + flurbiprofen axetil
The First People's Hospital of Lianyungang
Enhanced Recovery After Surgery
1 trial -
hylenex-facilitated subcutaneous Lactated Ringer's infusion
HALOZYME THERAPEUTICS, INC.
Dehydration
1 trial -
immunoglobulin G
Green Valley (Shanghai) Pharmaceuticals Co.,
Kawasaki Disease
1 trial -
inhaled treprostinil
United Therapeutics Europe Ltd
Pulmonary Arterial Hypertension
3 trials -
inotuzumab ozogamicin-dose level 2
Pfizer
Leukemia
1 trial -
insulin lispro injection, exenatide injection
The First People's Hospital of Lianyungang
Diabetes Mellitus, Type 2
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources